Inhaled iloprost for severe pulmonary hypertension

New England Journal of Medicine

Volumn 347, Issue 5, 2002, Pages 322-329

  Olschewski, Horst ^a   Simonneau, Gerald ^b   Galiè, Nazzareno ^c   Higenbottam, Timothy ^d   Naeije, Robert ^e   Rubin, Lewis J ^f   Nikkho, Sylvia ^g   Speich, Rudolf ^h   Hoeper, Marius M ⁱ   Behr, Jürgen ^j   Winkler, Jörg ^k   Sitbon, Olivier ^b   Popov, Wladimir ^h   Ardeschir Ghofrani, H ^a   Manes, Alessandra ^c   Kiely, David G ^d   Ewert, Ralph ^l   Meyer, Andreas ^m   Corris, Paul A ⁿ   Delcroix, Marion ^o   Gomez Sanchez, Miguel ^b,p   Siedentop, Harald ^g   Seeger, Werner ^a   more..

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^e ERASME HOSPITAL   (Belgium)

^f UCSD MEDICAL CENTER   (United States)

^g University Hospital ^*

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^l UNIVERSITY OF GREIFSWALD   (Germany)

^m UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁿ FREEMAN HOSPITAL   (United Kingdom)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; PLACEBO; PROSTACYCLIN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EXERCISE; FEMALE; FLUSHING; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; TREATMENT OUTCOME; VASODILATATION; VERTIGO;

ADMINISTRATION, INHALATION; DYSPNEA; EXERCISE TOLERANCE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; VASODILATOR AGENTS; WALKING;

EID: 0036682273     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa020204     Document Type: Article

References (33)

1. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
2. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
3. Caution with use of inhaled nitric oxide
4. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
5. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide
6. Life-threatening effects on discontinuing inhaled nitric oxide in children
7. Aerosolized prostacyclin in adult respiratory distress syndrome
8. Effects of aerosolized prostacyclin in severe pneumonia: Impact of fibrosis
9. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome
10. 2) versus inhaled nitric oxide in adult respiratory distress syndrome
11. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis
12. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD)
13. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
14. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
15. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension
16. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
17. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost
18. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension
19. Inhaled iloprost to treat severe pulmonary hypertension: An uncontrolled trial
20. Long term inhalation of iloprost in a child with primary pulmonary hypertension: An alternative to continuous infusion
21. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure
22. In vitro characterization of Ilomedin inhalation devices
23. The measurement of dyspnea: Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
24. EuroQol - A new facility for the measurement of health-related quality of life
25. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection
26. Statistical aspects of the analysis of data from retrospective studies of disease
27. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial
28. Bosentan therapy for pulmonary arterial hypertension
29. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial
30. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double blind, placebo-controlled trial
31. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
32. Comparison of inhalation of the prostacyclin analogue iloprost using different nebulizer systems in patients suffering from pulmonary hypertension